{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T23:45:06Z","timestamp":1780789506053,"version":"3.54.1"},"reference-count":76,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.annder.2013.01.442","type":"journal-article","created":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T01:06:18Z","timestamp":1362704778000},"page":"266-273","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Anomalies pigmentaires induites par les traitements anticanc\u00e9reux. Deuxi\u00e8me partie\u00a0: les th\u00e9rapies cibl\u00e9es"],"prefix":"10.1016","volume":"140","author":[{"given":"V.","family":"Sibaud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2013.01.442_bib0005","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1470-2045(05)70243-6","article-title":"Cutaneous side-effects of kinase inhibitors and blocking antibodies","volume":"6","author":"Robert","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annder.2013.01.442_bib0010","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.annder.2012.12.012","article-title":"Anomalies pigmentaires induites par les traitements anticanc\u00e9reux. Premi\u00e8re partie\u00a0: chimioth\u00e9rapies","volume":"140","author":"Sibaud","year":"2013","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2013.01.442_bib0015","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/annonc\/mdi279","article-title":"Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors","volume":"16","author":"Segaert","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annder.2013.01.442_bib0020","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jaad.2006.09.005","article-title":"Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management","volume":"56","author":"Hu","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2013.01.442_bib0025","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jaad.2005.10.010","article-title":"Dermatologic side effects associated with the epidermal growth factor receptor inhibitors","volume":"55","author":"Agero","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2013.01.442_bib0030","first-page":"1079","article-title":"Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities","volume":"19","author":"Lacouture","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.annder.2013.01.442_bib0035","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1159\/000335632","article-title":"Cutaneous drug eruptions associated with the use of new oncological drugs","volume":"97","author":"Belloni","year":"2012","journal-title":"Chem Immunol Allergy"},{"key":"10.1016\/j.annder.2013.01.442_bib0040","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc1970","article-title":"Mechanisms of cutaneous toxicities to EGFR inhibitors","volume":"6","author":"Lacouture","year":"2006","journal-title":"Nature Rev Cancer"},{"key":"10.1016\/j.annder.2013.01.442_bib0045","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1634\/theoncologist.2010-0082","article-title":"Does sunscreen prevent growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North central Cancer Treatment Group (NC05C4)","volume":"15","author":"Jatoi","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.annder.2013.01.442_bib0050","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1634\/theoncologist.2009-0055","article-title":"Expert consensus on the management of erlotinib-associated cutaneous toxicity in the UK","volume":"14","author":"Thatcher","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.annder.2013.01.442_bib0055","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2230.2011.04117.x","article-title":"Higher severity of erlotinib-induced rash is associated with lower skin phototype","volume":"36","author":"Luu","year":"2011","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.annder.2013.01.442_bib0060","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.anplas.2012.02.002","article-title":"Dermatologic adverse events of the new targeted anticancer therapies used in oncodermatology","volume":"57","author":"Sibaud","year":"2012","journal-title":"Ann Chir Plast Esthet"},{"key":"10.1016\/j.annder.2013.01.442_bib0065","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1684\/bdc.2011.1457","article-title":"Dermatologic side effects induced by new angiogenesis inhibitors","volume":"98","author":"Sibaud","year":"2011","journal-title":"Bull Cancer"},{"key":"10.1016\/j.annder.2013.01.442_bib0070","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1046\/j.1523-1747.1998.00272.x","article-title":"The SCF\/KIT pathway plays a critical role in the control of normal human melanocyte homeostasis","volume":"111","author":"Grichnik","year":"1998","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.annder.2013.01.442_bib0075","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1002\/cncr.11812","article-title":"Imatinib mesylate causes hypopigmentation in the skin","volume":"98","author":"Tsao","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.annder.2013.01.442_bib0080","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/annonc\/mdh068","article-title":"Pigmentary changes in chronic myeloid leukaemia patients treated with imatinib mesylate","volume":"15","author":"Arora","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annder.2013.01.442_bib0085","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1529-8019.2011.01431.x","article-title":"Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib","volume":"24","author":"Amitay-Laish","year":"2011","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.annder.2013.01.442_bib0090","series-title":"Cutaneous side effects induced by targeted anticancer therapies: a new dermatology","first-page":"41","article-title":"Cutaneous manifestations of BCR-ABL, c-KIT et PDGFR inhibitors","author":"Valeyrie-Allanore","year":"2010"},{"key":"10.1016\/j.annder.2013.01.442_bib0095","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1468-3083.2006.01981.x","article-title":"A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients","volume":"21","author":"Brazzelli","year":"2006","journal-title":"J Eur Acad Dermatol"},{"key":"10.1016\/j.annder.2013.01.442_bib0100","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1067\/mjd.2003.44","article-title":"Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukamias: a prospective study of 54\u00a0patients","volume":"48","author":"Valeyrie","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2013.01.442_bib0105","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5070\/D3472203P2","article-title":"Persistent cutaneous hyperpigmentation after tyrosine kinase inhibition with imatinib for GIST","volume":"14","author":"Alexandrescu","year":"2008","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.annder.2013.01.442_bib0110","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1001\/archdermatol.2009.263","article-title":"Disappearance of lentigines in a patient receiving imatinib treatment for familial gastrointestinal stromal tumor syndrome","volume":"145","author":"Campbell","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annder.2013.01.442_bib0115","first-page":"e65","article-title":"Reversible hair depigmentation in a patient treated with imatinib","volume":"35","author":"Mariani","year":"2010","journal-title":"Leukemia Res"},{"key":"10.1016\/j.annder.2013.01.442_bib0120","first-page":"1062","article-title":"Pigmentary changes in a patient treated with imatinib","volume":"10","author":"Balagula","year":"2011","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.annder.2013.01.442_bib0125","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1365-2133.2006.07359.x","article-title":"Imatinib mesylate inhibits melanogenesis in vitro","volume":"155","author":"Cario-Andre","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2013.01.442_bib0130","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1056\/NEJM200208083470614","article-title":"Imatinib mesylate and grey hair","volume":"347","author":"Etienne","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2013.01.442_bib0135","doi-asserted-by":"crossref","first-page":"s80","DOI":"10.1016\/j.jaad.2008.06.029","article-title":"Imatinib mesylate-induced repigmentation of vitiligo lesions in a patient with recurrent gastrointestinal stromal tumors","volume":"59","author":"Han","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2013.01.442_bib0140","first-page":"395","article-title":"Hair depigmentation during chemotherapy with dasatinib, a dual Bcr-Abl\/Src family tyrosine kinase inhibitor","volume":"8","author":"Sun","year":"2009","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.annder.2013.01.442_bib0145","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1053\/j.seminoncol.2012.01.009","article-title":"Advances in the management of cutaneous toxicities of targeted therapies","volume":"39","author":"Robert","year":"2012","journal-title":"Semin Oncol"},{"key":"10.1016\/j.annder.2013.01.442_bib0150","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s12105-011-0325-4","article-title":"Mucosal pigmentation caused by imatinib: report of three cases","volume":"6","author":"Li","year":"2012","journal-title":"Head Neck Pathol"},{"key":"10.1016\/j.annder.2013.01.442_bib0155","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1016\/j.jcms.2011.07.010","article-title":"Imatinib-associated hyperpigmentation of the palate in post-HSCT patient","volume":"40","author":"Resende","year":"2012","journal-title":"J Craniomaxillofac Surg"},{"key":"10.1016\/j.annder.2013.01.442_bib0160","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/j.tripleo.2010.11.006","article-title":"Oral pigmentation in the hard palate associated with imatinib mesylate therapy: a report of three cases","volume":"111","author":"Mattsson","year":"2011","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.annder.2013.01.442_bib0165","first-page":"24","article-title":"Diffuse pigmentation of the palate","volume":"100","author":"Lewis","year":"2009","journal-title":"J Okla Dent Assoc"},{"key":"10.1016\/j.annder.2013.01.442_bib0170","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1468-3083.2008.02706.x","article-title":"Imatinib-associated hyperpigmentation, a side effect that should be recognized","volume":"23","author":"Mcpherson","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2013.01.442_bib0175","series-title":"Cutaneous side effects induced by targeted anticancer therapies: a new dermatology","first-page":"41","article-title":"Dermatologic manifestations of angiogenesis inhibitors","author":"Sibaud","year":"2010"},{"key":"10.1016\/j.annder.2013.01.442_bib0180","first-page":"557","article-title":"Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib","volume":"16","author":"Rosenbaum","year":"2008","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.annder.2013.01.442_bib0185","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/j.1365-2133.2009.09290.x","article-title":"Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib","volume":"161","author":"Lee","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2013.01.442_bib0190","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2013.01.442_bib0195","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/S0140-6736(03)12805-X","article-title":"Tyrosine kinase inhibition and grey hair","volume":"361","author":"Robert","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.annder.2013.01.442_bib0200","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1001\/archderm.144.11.1525","article-title":"Sunitinib and periodic hair depigmentation due to temporary c-kit inhibition","volume":"144","author":"Hartmann","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annder.2013.01.442_bib0205","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.jaad.2008.12.030","article-title":"Skin depigmentation induced by sunitinib treatment of renal cell carcinoma","volume":"61","author":"Al Enazi","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2013.01.442_bib0210","first-page":"443","article-title":"Pazopanib\u2013the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma","volume":"71","author":"Keisner","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.annder.2013.01.442_bib0215","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s10637-011-9652-2","article-title":"The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis","volume":"30","author":"Balagula","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.annder.2013.01.442_bib0220","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1158\/1078-0432.CCR-08-2740","article-title":"Phase I trial of pazopanib in patients with advanced cancer","volume":"15","author":"Hurwitz","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annder.2013.01.442_bib0225","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annder.2013.01.442_bib0230","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1517\/14740331003596349","article-title":"Targeted therapy and hand-foot skin reaction in advanced renal cell carcinoma","volume":"9","author":"Yang","year":"2010","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.annder.2013.01.442_bib0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/1078-0432.CCR-11-0793","article-title":"Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics","volume":"17","author":"Yau","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annder.2013.01.442_bib0240","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S1470-2045(10)70203-5","article-title":"Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2\u00a0consortium study","volume":"11","author":"Bible","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annder.2013.01.442_bib0245","doi-asserted-by":"crossref","first-page":"e312","DOI":"10.1200\/JCO.2009.26.4432","article-title":"Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanib","volume":"28","author":"Sideras","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annder.2013.01.442_bib0250","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1001\/archderm.144.6.820","article-title":"Sorafenib-induced eruptive melanocytic lesions","volume":"144","author":"Kong","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annder.2013.01.442_bib0255","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.annder.2008.04.016","article-title":"Eruptive naevus associated with sorafenib treatment","volume":"135","author":"Bennani-Lahlou","year":"2008","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2013.01.442_bib0260","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1365-2133.2012.11155.x","article-title":"Manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma","volume":"167","author":"Anforth","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2013.01.442_bib0265","first-page":"1","article-title":"Dynamic changes in nevi of a patient with melanoma treated with vemurafenib: importance of sequential dermoscopy","author":"Haenssle","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annder.2013.01.442_bib0270","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jaad.2012.04.008","article-title":"Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study","volume":"67","author":"Chu","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2013.01.442_bib0275","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1200\/JCO.2011.41.1660","article-title":"Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition","volume":"30","author":"Zimmer","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annder.2013.01.442_bib0280","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMc1108651","article-title":"Vemurafenib in melanoma with BRAF V600E mutation","volume":"365","author":"Dalle","year":"2011","journal-title":"N Engl Med"},{"key":"10.1016\/j.annder.2013.01.442_bib0285","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1634\/theoncologist.2008-0261","article-title":"Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions","volume":"14","author":"Morabito","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.annder.2013.01.442_bib0290","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1200\/JCO.2009.23.6604","article-title":"Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer","volume":"28","author":"Wells","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annder.2013.01.442_bib0295","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1001\/archdermatol.2009.177","article-title":"Cutaneous pigmentation after photosensitivity induced by vandetanib therapy","volume":"145","author":"Kong","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annder.2013.01.442_bib0300","series-title":"Cutaneous side effects induced by targeted anticancer therapies: a new dermatology","first-page":"41","article-title":"Vandetanib (Zactima\u00ae)","author":"Robert","year":"2010"},{"key":"10.1016\/j.annder.2013.01.442_bib0305","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1200\/JCO.2010.28.5981","article-title":"Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer","volume":"29","author":"Natale","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annder.2013.01.442_bib0310","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1200\/JCO.2009.21.8479","article-title":"Severe photosensitivity reaction to vandetanib","volume":"27","author":"Chang","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annder.2013.01.442_bib0315","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S1470-2045(12)70335-2","article-title":"Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2\u00a0trial","volume":"13","author":"Leboulleux","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annder.2013.01.442_bib0320","doi-asserted-by":"crossref","first-page":"s314","DOI":"10.5021\/ad.2011.23.S3.S314","article-title":"Photosensitivity reactions to vandetanib: redevelopment after sequential treatment with docetaxel","volume":"23","author":"Son","year":"2011","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.annder.2013.01.442_bib0325","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1001\/archdermatol.2011.30","article-title":"Successful laser treatment of vandetanib-associated cutaneous pigmentation","volume":"147","author":"Brooks","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annder.2013.01.442_bib0330","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/1523-1747.ep12277571","article-title":"Photosensitivity and hyperpigmentation in amiodarone-treated patients: incidence, time course, and recovery","volume":"93","author":"Rappersberger","year":"1989","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.annder.2013.01.442_bib0335","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2013.01.442_bib0340","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2013.01.442_bib0345","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1158\/1078-0432.CCR-09-1024","article-title":"A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma","volume":"15","author":"Weber","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annder.2013.01.442_bib0350","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1634\/theoncologist.2009-0028","article-title":"What is the role of cytotoxic T lymphocyte-associated antigen 4\u00a0blockage in patients with metastatic melanoma?","volume":"14","author":"Robert","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.annder.2013.01.442_bib0355","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1517\/14712598.2012.675325","article-title":"Ipilimumab in the treatment of melanoma","volume":"12","author":"Trinh","year":"2012","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.annder.2013.01.442_bib0360","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1053\/j.seminoncol.2010.09.007","article-title":"The emerging toxicity profiles of anti-CTLA-4\u00a0antibodies across clinical indications","volume":"37","author":"Di Giacomo","year":"2010","journal-title":"Semin Oncol"},{"key":"10.1016\/j.annder.2013.01.442_bib0365","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annder.2013.01.442_bib0370","series-title":"Manifestations cutan\u00e9es des th\u00e9rapies cibl\u00e9es anticanc\u00e9reuses\u00a0: une Nouvelle Dermatologie","first-page":"89","article-title":"Manifestations dermatologiques des anticorps anti-CTLA-4","author":"Robert","year":"2010"},{"key":"10.1016\/j.annder.2013.01.442_bib0375","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1\u00a0antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2013.01.442_bib0380","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1\u00a0antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963813004742?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963813004742?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:00:17Z","timestamp":1758970817000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963813004742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":76,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S0151963813004742"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2013.01.442","relation":{},"ISSN":["0151-9638"],"issn-type":[{"value":"0151-9638","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anomalies pigmentaires induites par les traitements anticanc\u00e9reux. Deuxi\u00e8me partie\u00a0: les th\u00e9rapies cibl\u00e9es","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2013.01.442","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}